Netscientific Share Discussion Threads

[loafofbread] 18/6/2021 18:07

The Chinese will licence the Glycotest with £50M upfront and we will make it back to the placing price of £1.30.

[loafofbread] 18/6/2021 18:05

Our joint AZ test will sell millions and we will creep up to £1.25.

[loafofbread] 18/6/2021 18:04

Pdsb will double on vaccine news and we will still sit at £1.20!

[blakieboy7] 18/6/2021 17:59

Pdsb now 18% up - surely NSCI will catch up on Monday

[loafofbread] 18/6/2021 17:02

EDIT

PDSB now worth £10M and MCap down to £17M.

[blakieboy7] 18/6/2021 16:39

https://tdameritradenetwork.com/video/rB4A-HoZE0mBehtbJF0BIA

[blakieboy7] 18/6/2021 16:33

Pdsb up to 11 dollars

[the stigologist] 18/6/2021 12:43

PDSB insiders bought quite a lot of stock in the offering (given they will be optioned up to the hilt anyway this is a big signal in my book)

[blakieboy7] 17/6/2021 20:47

Pdsb up 7%

[4vik] 17/6/2021 20:39

Covid vaccine trial approval looks imminent.

[the stigologist] 17/6/2021 09:05

IIs who bought at 130p waking up or WH Ireland pulling their finger out ?

[loafofbread] 16/6/2021 22:22

About ProAxsis

ProAxsis Limited is a commercial diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.

This technology has been translated into a point-of-care test (NEATstik(R)), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik(R) enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha. Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

Can't wait for the RNS to say the test is ready.

M Cap of NSCI is such a gift.

[the stigologist] 16/6/2021 18:43

Watching PDSB Oncology R&D day now

Heard it was v.bullish

[blakieboy7] 16/6/2021 15:43

Pdsb is up 8%

[1airbag] 16/6/2021 12:28

if it goes to 60p, i'm buying a lot of shares....!

added to holding today.

[nextlink] 16/6/2021 11:23

Gap between your ears to be filled

[saint in exile] 16/6/2021 11:17

Remember saying this the other week letmepass...`High of 235p the other day. Expect to be back there soon enough. Nice fundraise`
Now we are heading for 60p apparently

[letmepass] 16/6/2021 09:27

Gap at 60p to be filled

[kalkaar] 16/6/2021 07:53

NetScientific follows its money as investee company announces plans to raise US$45mln

NetScientific PLC (LON:NSCI) said it is participating in the latest funding round by investee company PDS Biotechnology Corporation (NASDAQ:PDSB).

It said it is buying shares worth US$510,000 and is funding the transaction from a loan facility.

PDS said on Tuesday it plans to raise around US$45mln via the issue of new stock.

Once the fundraiser is complete, NetScientific expects its stake in the US biotech to be diluted down slightly to 4.86% from 5.7% currently. The holding is worth around £8.3mln at current prices.

PDS is a clinical-stage life sciences group whose main platform, Versamune, trains the immune system to unleash powerful targeted T-cell attacks that could “dramatically improve treatment and patient outcomes across the cancer spectrum”.

Dr Ilian Iliev, NetScientific chief executive who sits on the board of the US-listed investee firm, said: "Following a transformational year for PDS, and growing market recognition of the potential of its Versamune platform, this latest investment provides PDS with the resources to continue executing its ambitious strategy in the immuno-oncology space."

[kalkaar] 16/6/2021 07:45

noteworthy points from latest rns:

- original investment in PDS was funded by borrowing from major shareholder @10% pa
- NSCI has 1,286,000 shares in PDS
- additional investment of £363,000 in placing
- NSCI only subscribing for additional 60,000 shares in placing
- funded by major shareholder again until placing proceeds come in
- full loan will then be paid off
- diluted new ownership of 4.86%

major shareholder Melvin Lawson currently owns 22% of NSCI

surprised they've not gone for more!

[loafofbread] 16/6/2021 07:38

Interesting to see if that's all they wanted or all they could get?

I'm sure the PDSB RNS will say massively oversubscribed and we should be back above $10/11 by the week end.

[saint in exile] 16/6/2021 07:19

Holding reduced to 4.86%

[loafofbread] 15/6/2021 22:35

We have $10M from the placing and a further $2.5M in cash.

PDSB raise is $45M so approx $3M to us if we stay at 5.75%.

NSCI is still dirt cheap.